Under the joint lead of Frankfurt partner Prof Dr Michael Schlitt and Munich counsel Dr Sebastian Biller, globall law firm Hogan Lovells has advised MorphoSys AG (“MorphoSys”) in connection with the conclusion of a delisting agreement with Novartis in relation to a public delisting tender offer by Novartis and the related revocation of the admission of MorphoSys shares to trading on the regulated market of the Frankfurt Stock Exchange as well as the delisting of its American Depositary Shares (ADS) from the Nasdaq Global Market and the deregistration with the U.S. Securities and Exchange Commission (SEC).
The delisting tender offer by Novartis, which was offered to all MorphoSys shareholders to acquire their MorphoSys shares against payment of a cash consideration of EUR 68.00 per MorphoSys share, followed the voluntary public takeover offer by Novartis published in April 2024 and settled in May 2024.
MorphoSys is a global biopharmaceutical company, which develops and delivers innovative cancer medicines and brings them to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.
